Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
At 21 days, survival was 90 percent in anakinra group versus 56 percent in standard treatment group.
The biosimilar is now available for use in the treatment of RA and granulomatosis with polyangiitis and microscopic polyangiitis.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
Incidence of hypertension higher for adults on oral steroids for any of 6 chronic inflammatory diseases.
Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo® (Horizon Pharma).
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
Longer time to receipt more likely with older age, male sex, greater distance to nearest rheumatologist.
The FDA has approved Avsola (infliximab-axxq; Amgen), a biosimilar to Remicade (infliximab; Janssen Biotech).
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
